Actively Recruiting
Phase II Study of Envafolimab Alone or With Lenvatinib for Advanced Endometrial Cancer in Adult Women
Led by 3D Medicines (Sichuan) Co., Ltd. · Updated on 2026-03-25
108
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating envafolimab alone or combined with lenvatinib in patients with advanced endometrial cancer who cannot undergo curative surgery or radiation. This Phase II open-label, multi-center study aims to measure the objective response rate to these treatments. The study is sponsored by 3D Medicines Sichuan Co., Ltd. and focuses on patients who have previously undergone or cannot tolerate first-line platinum-based chemotherapy. Participants receive either envafolimab alone or envafolimab combined with lenvatinib. Envafolimab is given as a 400mg dose on Day 1 and Day 15 of the first 28-day treatment cycle, then once on Day 1 of each following cycle. Lenvatinib is taken orally at 20mg daily during each 28-day cycle for those in the combination group. Treatment continues up to approximately 24 months as patients are monitored. During the study, patients will undergo regular assessments including imaging reviews to measure tumor response, along with evaluations of treatment duration, disease control, time to response, progression-free survival, and overall survival. Researchers will also monitor organ function and safety throughout the treatment period. The total duration of participant involvement can be up to about 24 months, allowing long-term observation of treatment effects and outcomes.
CONDITIONS
Brief Title
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Research Team
B
bin She
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here